Search Results - Bernard Escudier

Refine Results
  1. 1
    Emerging immunotherapies for renal cell carcinoma

    Emerging immunotherapies for renal cell carcinoma by Bernard Escudier

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Axitinib for the Management of Metastatic Renal Cell Carcinoma

    Axitinib for the Management of Metastatic Renal Cell Carcinoma by Bernard Escudier, Martin Gore

    Published 2011
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Bernard Escudier, Vesa Kataja

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Nivolumab in renal cell carcinoma: latest evidence and clinical potential

    Nivolumab in renal cell carcinoma: latest evidence and clinical potential by Camille Mazza, Bernard Escudier, Laurence Albigès

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Sequential therapy in renal cell carcinoma

    Sequential therapy in renal cell carcinoma by Bernard Escudier, M. Gross Goupil, Christophe Massard, Karim Fizazi

    Published 2009
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Heat and Moisture Exchanger vs Heated Humidifier during Long-Term Mechanical Ventilation

    Heat and Moisture Exchanger vs Heated Humidifier during Long-Term Mechanical Ventilation by Benoît Misset, Bernard Escudier, Daniel Rivara, Bernard Leclercq, Gérard Nitenberg

    Published 1991
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

    A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma by Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma

    Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma by Robert J. Motzer, Bernard Escudier, Andrew Gannon, Robert A. Figlin

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma

    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma by Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma

    Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma by S. Antoun, Vickie E. Baracos, Laura Birdsell, Bernard Escudier, Michael B. Sawyer

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

    Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib by G. Mickisch, M. Gore, Bernard Escudier, Giuseppe Procopio, Stefan Walzer, Mark Nuijten

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

    Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma by Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape

    Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape by Salem Chouaı̈b, Yosra Messai, Sophie Couvé, Bernard Escudier, Meriem Hasmim, Muhammad Zaeem Noman

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Prognostic factors for survival in patients with brain metastases from renal cell carcinoma

    Prognostic factors for survival in patients with brain metastases from renal cell carcinoma by St�phane Culine, Mohamed Békradda, Andrew Kramar, Annie Rey, Bernard Escudier, Jean-Pierre Droz

    Published 1998
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Metastatic renal cell carcinoma management

    Metastatic renal cell carcinoma management by Flávio Lobo Heldwein, Bernard Escudier, Gordon K. Smyth, Carlos Ary Vargas Souto, Guy Vallancien

    Published 2009
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  16. 16
    Insulin and IGFs in renal cancer risk and progression

    Insulin and IGFs in renal cancer risk and progression by Wojciech Solarek, Anna M. Czarnecka, Bernard Escudier, Zofia F. Bielecka, Fei Lian, Cezary Szczylik

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  17. 17
    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma

    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma by Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma

    Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma by Emilie Viey, Gaëlle Fromont, Bernard Escudier, Yannis Morel, Sylvie Da Rocha, Salem Chouaı̈b, Anne Caignard

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels

    Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels by Gerald Batist, François Patenaude, P. Champagne, David Croteau, Carey Levinton, C. Hariton, Bernard Escudier, É. Dupont

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography by Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: